natgillin/translations-raw huggingface dataset:
Then gently let go of your skin. 
Zatim nježno otpustite nabor kože.
Do not use this medicine if you notice that the syringe is damaged, or the medicine is cloudy, distinctly brown, or has particles in it. 
Ovaj lijek se ne smije upotrijebiti ako primijetite da je štrcaljka oštećena ili ako je lijek mutan, izrazito smeđe boje ili sadrži čestice.
Each pen delivers only one dose. 
Jednom štrcaljkom može se primijeniti samo jedna doza.
There is no relevant use of Taltz in children below the age of 6 years in the treatment of moderate to severe plaque psoriasis. 
Nema relevantne primjene lijeka Taltz u djece mlađe od 6 godina za liječenje umjerene do teške plak psorijaze.
Patients in these studies had a diagnosis of psoriatic arthritis (Classification Criteria for Psoriatic Arthritis [CASPAR] criteria) for a median of 5.33 years. 
Classification Criteria for Psoriatic Arthritis, CASPAR]) bio je 5,33 godine.
The mean elimination half-life, as estimated from population pharmacokinetic analysis, is 13 days in patients with plaque psoriasis. 
procijenjena na temelju populacijske farmakokinetičke analize, iznosi 13 dana.
In the 2 clinical studies that included an active comparator (UNCOVER-2 and UNCOVER-3), the rate of serious adverse events was 1.9 % for both etanercept and for Taltz, and the rate of discontinuation due to adverse events was 1.2 % for etanercept and 2.0 % for Taltz. 
UNCOVER-3), stopa ozbiljnih štetnih događaja iznosila je 1,9% i uz etanercept i uz Taltz, dok je stopa prekida liječenja zbog štetnih događaja iznosila 1,2% uz etanercept i 2,0% uz Taltz.
Gently pinch and hold a fold of skin where you will inject. 
Nježno uhvatite nabor kože na mjestu gdje ćete injicirati lijek.
Plaque psoriasis - The first dose is 160 mg (two 80 mg injections) by subcutaneous injection. 
Plak psorijaza - Prva doza je 160 mg (dvije injekcije od 80 mg), a primjenjuje se injekcijom pod kožu.
Ixekizumab administration to cynomolgus monkeys for 39 weeks at subcutaneous doses up to 50 mg/kg weekly produced no organ toxicity or undesirable effects on immune function (e.g. T-cell dependent antibody response and NK cell activity). 
Primjena iksekizumaba u supkutanim dozama do 50 mg/kg na tjedan tijekom 39 tjedana u makaki majmuna nije uzrokovala toksičnost za organe niti neželjene učinke na funkciju imunološkog sustava
Efficacy and safety of Taltz was investigated in a multicenter, randomized, open-label, rater-blinded, parallel-group study (SPIRIT-H2H) compared to adalimumab (ADA) in 566 patients with PsA who were naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD). 
U multicentričnom, randomiziranom, otvorenom ispitivanju s paralelnim skupinama koje je bilo zaslijepljeno za ocjenitelja (SPIRIT-H2H) ispitivale su se djelotvornost i sigurnost lijeka Taltz u usporedbi s adalimumabom (ADA) u 566 bolesnika s psorijatičnim artritisom koji prethodno nisu primali biološke antireumatske lijekove koji modificiraju tijek bolesti (bDMARD).
A total of 3,119 patients were evaluated (1,161 patients on 80 mg every 4 weeks (Q4W), 1,167 patients on 80 mg every 2 weeks (Q2W) and 791 patients on placebo). 
Ukupno je ocijenjeno 3119 bolesnika (1161 bolesnik liječen dozom od 80 mg svaka 4 tjedna, 1167 bolesnika liječenih dozom od 80 mg svaka 2 tjedna i 791 bolesnik koji je primao placebo).
1 pre-filled syringe of 1 ml solution 2 pre-filled syringes of 1 ml solution 3 pre-filled syringes of 1 ml solution 
1 napunjena štrcaljka s 1 ml otopine 2 napunjene štrcaljke s 1 ml otopine 3 napunjene štrcaljke s 1 ml otopine
- hives. 
[engl.
The proportion of patients achieving a PASI 75, PASI 90, and PASI 100 response at Week 24 was greater with Taltz Q4W compared to placebo (p<0.001). 
Udio bolesnika koji su postigli odgovor PASI 75, PASI 90 i PASI 100 u 24. tjednu bio je veći pri primjeni lijeka Taltz svaka 4 tjedna u odnosu na placebo (p<0,001).
In SPIRIT-P1 and SPIRIT-P2, similar responses for ACR 20/50/70 were seen in patients with psoriatic arthritis regardless of whether they were on concomitant cDMARDs, including MTX treatment, or not. 
U ispitivanjima SPIRIT-P1 i SPIRIT-P2, u bolesnika s psorijatičnim artritisom opažene su slične stope odgovora ACR 20/50/70 neovisno o tome jesu li istodobno primali konvencionalne DMARD-ove,
There were also improvements demonstrated in fatigue as assessed by Fatigue severity NRS scores (p<0.001). 
Dokazana su i poboljšanja u pogledu umora, na temelju rezultata na brojčanoj ljestvici za ocjenu težine umora (p < 0,001).
Efficacy and safety of ixekizumab was also investigated in a double-blind study compared to ustekinumab with ixekizumab being superior on the primary study objective (PASI 90 response at week 12, Table 6). 
Izravno usporedno ispitivanje faze 3b nakon stavljanja lijeka u promet Djelotvornost i sigurnost iksekizumaba bile su ispitivane i u dvostruko slijepom ispitivanju u usporedbi s ustekinumabom, u kojem je iksekizumab ostvario superiornost s obzirom na primarni cilj ispitivanja (odgovor PASI 90 u 12. tjednu, tablica 6).
PASI-Response Rates from comparative study ixekizumab versus ustekinumab 
PASI - Stope odgovora usporednog ispitivanja iksekizumaba u odnosu na ustekinumab
Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies (see section 5.1). 
Taltz je sam ili u kombinaciji s metotreksatom indiciran za liječenje aktivnog psorijatičnog artritisa u odraslih bolesnika koji na jedan ili više lijekova koji modificiraju tijek bolesti (engl. disease-modifying anti-rheumatic drug, DMARD) nisu dovoljno dobro odgovorili ili ih ne podnose.
Difference from Placebo in Response Rate (95% CI) 
Razlika u stopi odgovora u odnosu na placebo (95% CI)
Other side effects that have been reported 
Ostale prijavljene nuspojave
Etanercept 50 mg twice weekly (N = 358) 
Etanercept 50 mg dvaput na tjedan (N = 358)
The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) every 4 weeks thereafter. 
Preporučena doza je 160 mg supkutanom injekcijom (dvije injekcije od 80 mg) u 0. tjednu, a zatim 80 mg (jedna injekcija) svaka 4 tjedna nakon toga.
points at week 12 (84.6% for Taltz Q2W, 79.2% for Taltz Q4W and 16.5% for placebo) and the benefit was sustained over time up to Week 60 in patients treated with Taltz who were sPGA (0 or 1) 
≥ 4 boda u 12. tjednu (84,6% uz Taltz svaka 2 tjedna; 79,2% uz Taltz svaka 4 tjedna i 16,5% uz placebo), a korisni su se učinci održali do 60. tjedna u bolesnika liječenih lijekom Taltz koji su ostvarili odgovor prema sPGA rezultatu (0 ili 1) u 12. tjednu.
Etanercept 50 mg twice weekly (N = 382) 
Etanercept 50 mg dvaput na tjedan (N = 382)
Finger grips minutes 
Hvatište za prste minuta
Contact your doctor, pharmacist or nurse. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri.
A. It is normal to have air bubbles in the pre-filled pen. 
O. Normalno je da se u napunjenoj brizgalici nalaze mjehurići zraka.
For both Taltz Q2W and Q4W: b p<0.01 and c p<0.001 compared with placebo. 
Za Taltz svaka 2 tjedna i Taltz svaka 4 tjedna: b p < 0,01 i c p < 0,001 u usporedbi s placebom.
For both studies, the primary endpoint was American College of Rheumatology (ACR) 20 response at Week 24. 
American College of Rheumatology, ACR) u 24. tjednu.
In the psoriatic arthritis studies, injection site reactions were more common in subjects with a body weight < 100 kg compared with the group with a body weight ≥ 100 kg (24 % 
U ispitivanjima primjene kod psorijatičnog artritisa, reakcije na mjestu injiciranja bile su češće u ispitanika tjelesne težine < 100 kg nego u onih tjelesne težine ≥ 100 kg (24% naspram 13% prema objedinjenim podacima iz skupina koje su primale lijek svaka 2 tjedna odnosno svaka 4 tjedna).
Postmarketing Phase 4, direct comparative study 
Izravno usporedno ispitivanje faze 4 nakon stavljanja lijeka u promet
decision should be made whether to discontinue breast-feeding or to discontinue Taltz taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. 
Uzimajući u obzir korist dojenja za dijete i dobrobit liječenja za ženu, mora se donijeti odluka hoće li se prekinuti dojenje ili liječenje lijekom Taltz.
List of adverse reactions in clinical studiesa and postmarketing reports System Organ Class 
Popis nuspojava iz kliničkih ispitivanjaa i prijava nakon stavljanja lijeka u promet
Inflammatory Bowel Disease 
Upalna bolest crijeva
Back of arm 
Stražnji dio nadlaktice
Q. What if there is a drop of liquid on the tip of the needle when I remove the needle cap? 
Što ako se na vrhu igle nalazi kapljica tekućine nakon što skinem zatvarač igle?
• 1 sharps container for disposal of syringes 
• 1 spremnik za oštre predmete za zbrinjavanje štrcaljki
53% of patients had concomitant use of MTX at a mean weekly dose of 15.8 mg. 67% of patients who had concomitant use of MTX had a dose of 15 mg or greater. 
tom je ispitivanju 85,3% bolesnika prethodno primilo ≥ 1 konvencionalni DMARD, dok je 53% bolesnika istodobno primalo MTX u srednjoj tjednoj dozi od 15,8 mg; 67% bolesnika koji su istodobno primjenjivali MTX primalo je dozu od 15 mg ili više.
- if you currently have an infection or if you have long-term or repeated infections. 
- ako trenutno imate neku infekciju ili ako imate dugotrajne ili opetovane infekcije - ako imate Crohnovu bolest - ako imate ulcerozni kolitis
In Psoriatic Arthritis Study 1 (SPIRIT-P1), patients naive to biologic therapy with active psoriatic arthritis were randomised to subcutaneous injections of placebo, adalimumab 40 mg once every 2 weeks (active control reference arm), Taltz 80 mg once every 2 weeks (Q2W), or 80 mg once every 4 weeks (Q4W). 
U ispitivanju SPIRIT-P1 (Psoriatic Arthritis Study 1) bolesnici s aktivnim psorijatičnim artritisom koji nisu prethodno liječeni biološkom terapijom bili su randomizirani za primanje supkutanih injekcija placeba, adalimumaba u dozi od 40 mg jedanput svaka 2 tjedna (s ulogom aktivne kontrolne skupine ispitivanja), lijeka Taltz u dozi od 80 mg jedanput svaka 2 tjedna ili lijeka Taltz u dozi od 80 mg jedanput svaka 4 tjedna.
Taltz is given by injection under your skin (subcutaneous injection). 
Taltz se primjenjuje injekcijom pod kožu (supkutanom injekcijom).
The percentage of patients with no radiographic joint damage progression from randomisation to Week 52 was 90.9% for placebo/Taltz Q4W, 85.6% for Taltz Q4W/Taltz Q4W, and 89.4% for adalimumab/Taltz Q4W. 
Postotak bolesnika bez radiološke progresije oštećenja zglobova od randomizacije do 52. tjedna bio je 90,0% za placebo/Taltz svaka 4 tjedna, 85,6% za Taltz svaka 4 tjedna/Taltz svaka 4 tjedna te 89,4% za adalimumab/Taltz svaka 4 tjedna.
When you dispose of syringes and the sharps container: 
Pri zbrinjavanju štrcaljki i spremnika za oštre predmete:
Over 58.9% and 22.3% of the psoriatic arthritis patients had enthesitis and dactylitis at baseline, respectively. 
Više od 58,9% bolesnika s psorijatičnim artritisom je na početku ispitivanja imalo entezitis, a više od 22,3% njih daktilitis.
- The other ingredients are sodium citrate; citric acid, anhydrous; sodium chloride; polysorbate 80; water for injections. 
- Drugi sastojci su natrijev citrat, bezvodna citratna kiselina, natrijev klorid, polisorbat 80 i voda za injekcije.
The instructions for using the syringe, included with the package leaflet, must be followed carefully. 
Moraju se pažljivo slijediti upute za uporabu brizgalice, koje su priložene uz uputu o lijeku.
23.4 % of patients had a history of psoriatic arthritis at baseline. 
Na početku ispitivanja, 23,4% bolesnika imalo je psorijatični artritis u anamnezi.
ONLY. 
Co.
• The syringe must not be shaken. 
• Štrcaljka se ne smije tresti.
Efficacy in Non-Responders to Etanercept: For patients identified as an sPGA (0,1) non-responder to etanercept at Week 12 in UNCOVER-2 (N = 200) and who were switched to Taltz 80 mg Q4W after a 4 week washout period, 73 % and 83.5 % of patients were able to achieve sPGA (0,1) and PASI 75, respectively, after 12 weeks of being treated with Taltz. 
Djelotvornost u bolesnika koji nisu odgovorili na etanercept: Među bolesnicima za koje se utvrdilo da nisu ostvarili odgovor na etanercept prema sPGA rezultatu (0, 1) u 12. tjednu ispitivanja UNCOVER-2 (N = 200) i koji su prebačeni na Taltz u dozi od 80 mg svaka 4 tjedna nakon 4-tjednog razdoblja ispiranja, 73% bolesnika ostvarilo je sPGA odgovor (0, 1), a njih 83,5% odgovor PASI 75 nakon
In patients with pre-existing dactylitis or enthesitis, treatment with Taltz Q4W resulted in improvement in dactylitis and enthesitis at Week 24 compared to placebo (resolution: 78% vs. 24%; p<0.001, and 39% vs. 21%; p<0.01, respectively). 
U bolesnika s od prije postojećim daktilitisom ili entezitisom, liječenje lijekom Taltz svaka 4 tjedna doveo je do poboljšanja daktilitisa i entezitisa u 24. tjednu, u usporedbi s placebom (povlačenje 78% u odnosu na 24%; p<0,001, te 39% u odnosu na 21%; p<0,01).
In psoriatic arthritis, two placebo-controlled phase III studies were integrated to evaluate the safety of Taltz in comparison to placebo up to 24 weeks after treatment initiation. 
Kod psorijatičnog artritisa, objedinjeni su podaci iz dva placebom kontrolirana ispitivanja faze III radi ocjene sigurnosti lijeka Taltz u usporedbi s placebom tijekom razdoblja do 24 tjedna nakon početka liječenja.
Abbreviations: ACR 20/50/70 = American College of Rheumatology 20%/50%/70% response rate; ADA = adalimumab; BSA = body surface area; CI = confidence interval; Q4W = Taltz 80 mg every 4 weeks; Q2W = Taltz 80 mg every 2 weeks; N = number of patients in the analysis population; n = number of patients in the specified category; NRI = non-responder imputation; PASI 100 = psoriasis area and severity index 100% improvement; PBO = placebo. 
Kratice: ACR 20/50/70 = stopa odgovora od 20%/50%/70% prema kriterijima Američkog reumatološkog društva; ADA = adalimumab; BSA = površina tijela (body surface area); CI = interval pouzdanosti; N = broj bolesnika u populaciji uključenoj u analizu; n = broj bolesnika u specificiranoj kategoriji; NRI = eng.
Physical function and health-related quality of life In both SPIRIT-P1 and SPIRIT-P2, patients treated with Taltz Q2W (p<0.001) and Q4W (p<0.001) showed significant improvement in physical function compared to patients treated with placebo as assessed by Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24, and maintained at Week 52 in SPIRIT-P1. 
U oba su ispitivanja (SPIRIT-P1 i SPIRIT P2) bolesnici liječeni lijekom Taltz svaka 2 tjedna (p < 0,001) odnosno svaka 4 tjedna (p < 0,001) ostvarili značajno poboljšanje tjelesne funkcije u odnosu na bolesnike koji su primali placebo, što se ocjenjivalo indeksom onesposobljenosti prema Upitniku za ocjenu zdravstvenog stanja (engl.
Twist off the base cap. 
Odvrnite i skinite zatvarač baze.
1b Gather the supplies for your injection: 
1b Prikupite pribor za primjenu injekcije: • 1 vatu natopljenu alkoholom
For sPGA (0,1) responders at Week 12 re-randomised to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA ≥ 3) was 164 days in integrated UNCOVER-1 and UNCOVER-2 studies. 
Među bolesnicima koji su u 12. tjednu ostvarili odgovor prema sPGA rezultatu (0, 1) i kojima je ponovnom randomizacijom dodijeljen prekid liječenja (tj. primjena placeba), medijan vremena do relapsa (sPGA ≥ 3) iznosio je 164 dana prema objedinjenim podacima iz ispitivanja UNCOVER-1 i UNCOVER-2.
Infection rates observed in psoriatic arthritis clinical studies were similar to those observed in the plaque psoriasis studies with the exception of the frequencies of the adverse reactions of influenza and conjunctivitis which were common in patients with psoriatic arthritis. 
Stope infekcija opažene u kliničkim ispitivanjima kod psorijatičng artritisa bile su slične onima opaženima u ispitivanjima kod plak psorijaze, uz izuzetak učestalosti gripe i konjunktivitisa, koji su u bolesnika s psorijatičnim artritisom bile česte nuspojave.
- if you have recently had or are due to have a vaccination. 
- ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove - ako ste nedavno primili ili trebate primiti cjepivo.
Read the “Instructions for Use” for the pen carefully before using Taltz. 
"Upute za uporabu" brizgalice prije nego što primijenite Taltz.
Serious infections occurred in 13 (0.6 %) of patients treated with Taltz and in 3 (0.4 %) of patients treated with placebo (see section 4.4). 
3 (0,4%) bolesnika koja su primala placebo (vidjeti dio 4.4).
In plaque psoriasis, three placebo-controlled phase III studies were integrated to evaluate the safety of Taltz in comparison to placebo up to 12 weeks after treatment initiation. 
Kod plak psorijaze, objedinjeni su podaci iz tri placebom kontrolirana ispitivanja faze III radi ocjene sigurnosti lijeka Taltz u usporedbi s placebom tijekom razdoblja do 12 tjedana nakon početka liječenja.
The pharmacokinetic properties of Taltz observed in psoriatic arthritis patients were similar to those displayed in plaque psoriasis patients. 
Farmakokinetička svojstva lijeka Taltz opažena u bolesnika s psorijatičnim artritisom bila su slična onima u bolesnika s plak psorijazom.
• Keep the pre-filled pen out of the reach and sight of children. 
• Čuvajte napunjenu brizgalicu izvan dohvata i pogleda djece.
Of the 3,866 patients enrolled in these placebo-controlled studies, 64 % had received prior systemic therapy (biologic, conventional systemic or psoralen and ultraviolet A (PUVA)), 43.5 % had received prior phototherapy, 49.3 % had received prior conventional systemic therapy, and 26.4 % had received prior biologic therapy for the treatment of psoriasis. 
Od 3866 bolesnika uključenih u ta placebom kontrolirana ispitivanja, njih 64% prethodno je za liječenje psorijaze primalo sistemsku terapiju (biološku terapiju, konvencionalnu sistemsku terapiju ili terapiju psoralenom i ultraljubičastim
(Based on adverse reactions data from 4,204 patients with moderate to severe plaque psoriasis [4,729.7 patient years] and 1,117 patients with active psoriatic arthritis [1,050.6 patient years] who have received at least 1 dose of ixekizumab.) 
Opis odabranih nuspojava (Na temelju podataka o nuspojavama zabilježenim u 4204 bolesnika s umjerenom do teškom plak psorijazom [4729,7 bolesnik-godina] i 1117 bolesnika s aktivnim psorijatičnim artritisom
Frequency 
Sexual Frequency
Renal or hepatic impairment Taltz has not been studied in these patient populations. 
Taltz nije ispitivan u tim populacijama bolesnika.
Patients were randomised (1:2:2:2) to receive either placebo, or Taltz (80 mg every two or four weeks [Q2W or Q4W] following a 160 mg starting dose) or etanercept 50 mg twice weekly for 12 weeks. 
Bolesnici su bili randomizirani (1:2:2:2) za primanje placeba, lijeka Taltz (80 mg svaka dva ili četiri tjedna nakon početne doze od 160 mg) ili etanercepta u dozi od 50 mg dvaput na tjedan tijekom 12 tjedana.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PRE-FILLED SYRINGE 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - NAPUNJENA ŠTRCALJKA
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PRE-FILLED PEN 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - NAPUNJENA BRIZGALICA
The frequency of neutropenia and thrombocytopenia in psoriatic arthritis clinical studies is similar to that observed in the plaque psoriasis studies. 
Učestalost neutropenije i trombocitopenije u kliničkim ispitivanjima kod psorijatičnog artritisa slična je onoj opaženoj u ispitivanjima kod plak psorijaze.
At Week 52, the mean change from baseline in mTSS was 0.27 for placebo/Taltz Q4W, 0.54 for Taltz Q4W/Taltz Q4W, and 0.32 for adalimumab/Taltz Q4W. 
U 52. tjednu srednja vrijednost promjene u usporedbi s početnom vrijednošću mTSS rezultata bila je 0,27 za placebo/Taltz svaka 4 tjedna, 0,54 za Taltz svaka 4 tjedna/Taltz svaka 4 tjedna te 0,32 za adalimumab/Taltz svaka 4 tjedna.
Taltz was efficacious in the maintenance of response in systemic treatment-naive, biologic-naive, biologic/anti-TNF-exposed and biologic/anti-TNF-failure patients. 
Taltz je bio djelotvoran u održavanju odgovora u bolesnika prethodno neliječenih sistemskom terapijom, bolesnika prethodno neliječenih biološkom terapijom, bolesnika prethodno izloženih biološkim/anti-TNF lijekovima i bolesnika koji nisu odgovorili na prethodno liječenje biološkim/anti-TNF lijekovima.
• Keep the syringe out of the reach and sight of children. 
• Čuvajte štrcaljku izvan dohvata i pogleda djece.
Read the “Instructions for Use” for the syringe carefully before using Taltz. 
"Upute za uporabu" štrcaljke prije nego što primijenite Taltz.
Taltz contains the active substance ixekizumab. 
Taltz sadrži djelatnu tvar iksekizumab.
Patients randomised to Taltz who were sPGA (0,1) responders (static Physicians Global Assessment) at Week 12 were re-randomised to receive placebo or Taltz for an additional 48 weeks (UNCOVER-1 and UNCOVER-2); patients randomised to placebo, etanercept or Taltz who were sPGA (0,1) nonresponders received Taltz for up to 48 weeks. 
Bolesnici randomizirani za liječenje lijekom Taltz koji su u 12. tjednu ostvarili odgovor prema sPGA (od engl. static Physician's Global Assessment; statična opća ocjena liječnika) rezultatu (0, 1) bili su ponovno randomizirani za primanje placeba ili lijeka Taltz tijekom dodatnih 48 tjedana (UNCOVER-1 i UNCOVER-2); bolesnici randomizirani za primanje placeba, etanercepta ili lijeka Taltz koji nisu ostvarili odgovor prema sPGA rezultatu (0, 1) primali su lijek Taltz tijekom razdoblja do 48 tjedana.
Dispose of the pre-filled pen in a closable, puncture-resistant sharps container. 
Zbrinite brizgalicu u neprobojan spremnik za oštre predmete koji se može zatvoriti.
In SPIRIT-P1and SPIRIT-P2, improvements were shown in all components of the ACR scores including patient assessment of pain. 
U ispitivanjima SPIRIT-P1 i SPIRIT-P2 zabilježena su poboljšanja svih sastavnica ACR odgovora,
After the 160 mg starting dose, steady state was achieved by Week 8 with the 80 mg Q2W dosing regimen. 
Nakon početne doze od 160 mg, stanje dinamičke ravnoteže uz režim doziranja 80 mg svaka 2 tjedna postignuto je do 8. tjedna.
At Week 12 and across studies, Taltz was associated with statistically significant improvement in Health-related Quality of Life as assessed by mean decrease ranges from baseline in the Dermatology Life Quality Index (DLQI) (Taltz 80 mg Q2W from -10.2 to -11.1, Taltz 80 mg Q4W from -9.4 to10.7, etanercept from -7.7 to -8.0 and placebo -1.0 to -2.0). 
Dermatology Life Quality Index, DLQI) od početnog rezultata (Taltz 80 mg svaka 2 tjedna: od -10,2 do -11,1; Taltz 80 mg svaka 4 tjedna: od -9,4 do -10,7; etanercept: od -7,7 do -8,0; placebo: od -1,0 do -2,0).
The solution/the syringe must not be shaken. 
Otopina/brizgalica se ne smije tresti.
Comprehensive instructions for administration are given in the package leaflet. 
Opsežne upute za primjenu navode se u uputi o lijeku.
Patients receiving adalimumab or placebo were re-randomised 1:1 to Taltz Q2W or Q4W at week 16 or 24 based on responder status. 
Bolesnici koji su primali adalimumab ili placebo bili su ponovno randomizirani u omjeru 1:1 za primanje lijeka Taltz svaka 2 tjedna ili svaka 4 tjedna u 16. ili 24. tjednu, ovisno o statusu postignutog odgovora.
Read the full Instructions for Use and the Patient Information Leaflet for Taltz inside this box to learn more about your medicine. 
Za više informacije o ovom lijeku, pročitajte cjelovite upute za uporabu i uputu o lijeku Taltz koja se nalazi u ovoj kutiji.
• If you have questions or need help with your pre-filled syringe, call your doctor, pharmacist or nurse. 
• Ako imate pitanja ili trebate pomoć s napunjenom štrcaljkom, obratite se svom liječniku,